ALVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alvotech SA is not a strong buy at this time given the investor's long-term strategy and beginner level. The stock shows no clear technical or sentiment-driven signals for immediate upside, and analysts have lowered price targets with mixed ratings. While the company has raised significant funds recently, its high leverage and pending U.S. approvals in Q4 2026 create uncertainty. A hold position is recommended until clearer positive catalysts emerge.
The MACD is slightly positive at 0.0252, indicating mild bullish momentum, but it is contracting. RSI is neutral at 50.26, and moving averages are converging, showing no clear trend. Support and resistance levels suggest the stock is trading near a pivot point at $4.037.
Alvotech successfully raised $165 million through public offerings and private placements, which could support its biosimilar development. UBS maintains a Buy rating, citing confidence in the company's remediation plan and potential U.S. approvals by year-end 2026.
Analysts from Deutsche Bank and Barclays have lowered price targets to $4, citing concerns over high leverage, financial flexibility, and pending U.S. approvals. Barclays maintains an Underweight rating, expecting the stock to remain in a holding pattern. No significant hedge fund or insider trading activity.
No financial data available for the latest quarter. However, the company has raised significant capital recently, which may support its operations and R&D.
Analysts have mixed views. UBS is optimistic with a Buy rating and a $6 price target, while Deutsche Bank and Barclays have lowered their targets to $4 and maintain Hold and Underweight ratings, respectively. Concerns over financial flexibility and pending approvals dominate the sentiment.
